Xiaojin Pill

ApprovedSmall molecule

ZZhejiang Provincial People's Hospital

Xiaojin Pill is one of 6 small molecule programs targeting Thyroid Nodule. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid NoduleActive, not recruiting

Thyroid NoduleApproved

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Thyroid Nodule

#DrugCompanyPhaseTrials

Xiaojin Pill

ZZhejiang Provincial People's Hospital

Approved

1 2

Ethanol

Roche

Phase 1

1 3

Radioactive Iodine

UUniversity of Helsinki

Phase 3

1 4

Alcohol

Astellas

Phase 1

—5

Synthroid

IInstitut Jerome Lejeune

Preclinical

—6

Amoxil

GGlobal Antibiotics Research and Development Partnership

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalNot yet recruiting

Thyroid Nodule

NCT07340177

Clinical

Trials by Indication[1]

Thyroid Nodule1 trial

Xiaojin Pill/Neixiao Luoli Pill for the Treatment of Thyroid Nodules

Not yet recruiting·ZZhejiang Provincial People's Hospital·Phase 4·NCT07340177·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Xiaojin Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xiaojin Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xiaojin Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang Provincial People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: ZZhejiang Provincial People's Hospital

Xiaojin Pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Thyroid Nodule1 trial

References

Drug Info

Quick Facts

Related News